Literature DB >> 15147109

Tolerability issues during long-term treatment with antidepressants.

Paolo Cassano1, Maurizio Fava.   

Abstract

Depressive disorders are highly prevalent in the general population. Long-term treatment with antidepressants consolidates the improvement obtained during the acute phase of the treatment and prevents relapses and recurrences of the disorder. On the other hand, there is growing evidence that antidepressant side effects may limit patients' quality of life and social functioning, as well as affect patients' health and treatment adherence. Most studies concerning antidepressant treatment have focused on short-term tolerability, ignoring both early-onset persistent side effects and late-onset side effects that are reported during long-term treatment. Nevertheless, these long-term treatment side effects are likely to have a dramatic impact on patient outcome and treatment adherence. Common long-term side effects of antidepressants are weight gain, sexual dysfunction, sleep disturbances, fatigue, apathy, and cognitive impairment (e.g., working memory dysfunction). Usual strategies for the management of these long-term side effects are: changing drug daily schedule, various augmentation therapies, antidepressant switches, drug-holidays, and dose tapering, with the latter two strategies being strongly discouraged on the basis of concerns that patients' depressive episodes may return. Selective serotonin reuptake inhibitors (SSRIs) and atypical antidepressants (e.g., venlafaxine, bupropion, and nefazodone) show a relatively favorable short-term as well as long-term tolerability compared with older drugs (e.g., tricyclics and monoamine oxidase inhibitors). Therefore, clinicians are likely to prefer them in usual practice, especially among patients requiring maintenance treatment. The present review focuses on management of long-term side effects.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15147109     DOI: 10.1080/10401230490281618

Source DB:  PubMed          Journal:  Ann Clin Psychiatry        ISSN: 1040-1237            Impact factor:   1.567


  35 in total

1.  Unified protocol for the discontinuation of long-term serotonin reuptake inhibitors in obsessive compulsive disorder: Study protocol and methods.

Authors:  Christina L Boisseau; Steven A Rasmussen
Journal:  Contemp Clin Trials       Date:  2018-01-03       Impact factor: 2.226

2.  Astrocytic GABAB Receptors in Mouse Hippocampus Control Responses to Behavioral Challenges through Astrocytic BDNF.

Authors:  Ji-Hong Liu; Ze-Lin Li; Yi-Si Liu; Huai-De Chu; Neng-Yuan Hu; Ding-Yu Wu; Lang Huang; Shu-Ji Li; Xiao-Wen Li; Jian-Ming Yang; Tian-Ming Gao
Journal:  Neurosci Bull       Date:  2020-03-12       Impact factor: 5.203

3.  A Prospective Surveillance of Pharmacovigilance of Psychotropic Medicines in a Developing Country.

Authors:  Jisha Myalil Lucca; Madhan Ramesh; Gurumurthy Parthasarathi; Dushad Ram
Journal:  Psychopharmacol Bull       Date:  2016-03-01

4.  The Safety and Tolerability Profile of Vilazodone, A Novel Antidepressant for the Treatment of Major Depressive Disorder.

Authors:  Michael Liebowitz; Harry A Croft; Daniel K Kajdasz; Heidi Whalen; Susan Gallipoli; Maria Athanasiou; Carol R Reed
Journal:  Psychopharmacol Bull       Date:  2011-09-15

5.  Enhancement of Aggression Induced by Isolation Rearing is Associated with a Lack of Central Serotonin.

Authors:  Yiqiong Liu; Yunong Sun; Xiaoyan Zhao; Ji-Young Kim; Lu Luo; Qian Wang; Xiaolu Meng; Yonghui Li; Nan Sui; Zhou-Feng Chen; Chuxiong Pan; Liang Li; Yan Zhang
Journal:  Neurosci Bull       Date:  2019-04-11       Impact factor: 5.203

6.  Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment.

Authors:  Francis J McMahon; Silvia Buervenich; Dennis Charney; Robert Lipsky; A John Rush; Alexander F Wilson; Alexa J M Sorant; George J Papanicolaou; Gonzalo Laje; Maurizio Fava; Madhukar H Trivedi; Stephen R Wisniewski; Husseini Manji
Journal:  Am J Hum Genet       Date:  2006-03-20       Impact factor: 11.025

Review 7.  Nutrition and depression: implications for improving mental health among childbearing-aged women.

Authors:  Lisa M Bodnar; Katherine L Wisner
Journal:  Biol Psychiatry       Date:  2005-07-25       Impact factor: 13.382

8.  Conceptual models of treatment in depressed Hispanic patients.

Authors:  Alison Karasz; Liza Watkins
Journal:  Ann Fam Med       Date:  2006 Nov-Dec       Impact factor: 5.166

9.  PI3K/Akt signaling pathway in the basolateral amygdala mediates the rapid antidepressant-like effects of trefoil factor 3.

Authors:  Hai-Shui Shi; Wei-Li Zhu; Jian-Feng Liu; Yi-Xiao Luo; Ji-Jian Si; Shen-Jun Wang; Yan-Xue Xue; Zeng-Bo Ding; Jie Shi; Lin Lu
Journal:  Neuropsychopharmacology       Date:  2012-07-25       Impact factor: 7.853

10.  Possible cross-sensitivity between sertraline and paroxetine in a panic disorder patient.

Authors:  Praveen H Khairkar; Govind M Bang; Adarshlata B Singh; Prashant G Tiple
Journal:  Indian J Pharmacol       Date:  2010-04       Impact factor: 1.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.